News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEvents
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Jill Williams, RN, BSN, NP

Advertisement

Articles by Jill Williams, RN, BSN, NP

Reducing Central Line-Associated Bloodstream Infections

ByLisa Truini-Pittman, RN, BSN, MPH, OCN, Linda Sullivan, RN, Kirsten Pedersen, RN, BSN, OCN, Tanaz Mistry, RN, BSN, OCN, NP,Jill Williams, RN, BSN, NP
May 15th 2015

Decreasing hospital associated infection rates including Central Line–Associated Bloodstream Infections is an issue of ongoing focus nationwide.

Advertisement

Latest Updated Articles

  • Reducing Central Line-Associated Bloodstream Infections
    Reducing Central Line-Associated Bloodstream Infections

    Published: May 15th 2015 | Updated:



Advertisement
Advertisement

Trending on Oncology Nursing News

1

When Are TKIs Too Aggressive for a Patient With Renal Cell Carcinoma?

2

Linking Patient Experience With Next Steps in Renal Cell Carcinoma

3

Why Does Rina-S Target Folate Receptor Alpha in Endometrial Cancer?

4

Real-World Data Favor GLP-1 vs Aspirin in Colorectal Cancer Prevention

5

JSKN003 Given FDA Breakthrough Therapy Status in HER2+ PROC

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us